Pfizer Talking to Trump Administration About Priority Vouchers

Pfizer Inc. is looking to join its rivals in getting priority review vouchers, Chief Executive Officer Albert Bourla said, after several drugmakers received the express passes after striking deals with the White House on pricing.

The national priority voucher program was designed to support US interests and speed reviews for companies that are working with the administration on critical health goals. Many large drugmakers that reached agreements got the US Food and Drug Administration vouchers that can cut review times to as little as one month, from the current process that can take 10 months to a year.